BR112022003811A2 - Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução - Google Patents

Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução

Info

Publication number
BR112022003811A2
BR112022003811A2 BR112022003811A BR112022003811A BR112022003811A2 BR 112022003811 A2 BR112022003811 A2 BR 112022003811A2 BR 112022003811 A BR112022003811 A BR 112022003811A BR 112022003811 A BR112022003811 A BR 112022003811A BR 112022003811 A2 BR112022003811 A2 BR 112022003811A2
Authority
BR
Brazil
Prior art keywords
post
diabetic retinopathy
human anti
treatment
fully human
Prior art date
Application number
BR112022003811A
Other languages
English (en)
Inventor
Joseph Pakola Stephen
Van Everen Sherri
I Yoo Jesse
Maganbhai Patel Samir
Arvind Ghanekar Avanti
Ray O'berry Anthony
Rees Irwin-Pack Kim
Thomas Curtiss Darin
Original Assignee
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc filed Critical Regenxbio Inc
Publication of BR112022003811A2 publication Critical patent/BR112022003811A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

TRATAMENTO DE RETINOPATIA DIABÉTICA COM FAB ANTI-VEGF TOTALMENTE HUMANO MODIFICADO PÓS-TRADUÇÃO. Trata se de composições e métodos para a entrega de um anticorpo monoclonal totalmente humano modificado pós tradução (HuPTM) ("mAb") ou o fragmento de ligação ao antígeno de um mAb contra o fator de crescimento endotelial vascular humano ("hVEGF") - tal como, por exemplo, um fragmento de ligação ao antígeno anti hVEGF totalmente glicosilado humano (HuGly) - para a retina/humor vítreo no(s) olho(s) de sujeitos humanos diagnosticados com retinopatia diabética.
BR112022003811A 2019-08-26 2020-08-25 Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução BR112022003811A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962891799P 2019-08-26 2019-08-26
US201962902352P 2019-09-18 2019-09-18
US202063004258P 2020-04-02 2020-04-02
PCT/US2020/047733 WO2021041373A1 (en) 2019-08-26 2020-08-25 Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab

Publications (1)

Publication Number Publication Date
BR112022003811A2 true BR112022003811A2 (pt) 2022-11-16

Family

ID=72473961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003811A BR112022003811A2 (pt) 2019-08-26 2020-08-25 Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução

Country Status (12)

Country Link
US (1) US20220280608A1 (pt)
EP (1) EP4021936A1 (pt)
JP (1) JP2022545967A (pt)
KR (1) KR20220051246A (pt)
CN (1) CN114502197A (pt)
AU (1) AU2020336314A1 (pt)
BR (1) BR112022003811A2 (pt)
CA (1) CA3149401A1 (pt)
IL (1) IL290863A (pt)
MX (1) MX2022002366A (pt)
TW (1) TW202122419A (pt)
WO (1) WO2021041373A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR
WO2024073669A1 (en) 2022-09-30 2024-04-04 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804561B1 (en) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白
IL134643A0 (en) 1997-08-27 2001-04-30 Ariad Gene Therapeutics Inc Chimeric transcriptional activators and compositions and uses related thereto
CA2318402A1 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
EP1053241A1 (en) 1998-02-13 2000-11-22 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
DK1204739T3 (da) 1999-08-09 2008-10-20 Targeted Genetics Corp Forögelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP2338900B1 (en) 2001-11-13 2014-01-01 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof
CA2469785C (en) 2001-12-17 2014-04-22 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
CN102199626B (zh) 2003-09-30 2015-06-24 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
CN101203613B (zh) 2005-04-07 2012-12-12 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
CN107828820B (zh) 2010-10-27 2022-06-07 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
KR20220056884A (ko) 2011-04-22 2022-05-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
JP6385920B2 (ja) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー アデノ随伴ウイルスプラスミド及びベクター
ES2729166T3 (es) 2012-05-24 2019-10-30 Altaviz Llc Inyector de fluido viscoso
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
EP3060575B1 (en) 2013-10-11 2018-12-05 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
JP6768686B2 (ja) 2014-11-28 2020-10-14 ヴィジョニスティ オイ 眼科治療用器具
USD878575S1 (en) 2015-11-24 2020-03-17 Visionisti Oy Hand operated medical instrument
KR20240005973A (ko) 2016-04-15 2024-01-12 리젠엑스바이오 인크. 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
AU2017248731A1 (en) 2016-04-15 2018-10-18 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
WO2019067540A1 (en) 2017-09-27 2019-04-04 Regenxbio Inc. TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB
EP3697449A1 (en) * 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
US10912883B2 (en) 2017-11-04 2021-02-09 Altaviz, Llc Gas-powered fluid injection system
EP3703792B1 (en) 2017-11-04 2023-10-11 Altaviz, LLC Injection devices and methods for making them

Also Published As

Publication number Publication date
CN114502197A (zh) 2022-05-13
TW202122419A (zh) 2021-06-16
JP2022545967A (ja) 2022-11-01
WO2021041373A8 (en) 2023-01-05
MX2022002366A (es) 2022-07-19
WO2021041373A1 (en) 2021-03-04
EP4021936A1 (en) 2022-07-06
US20220280608A1 (en) 2022-09-08
AU2020336314A1 (en) 2022-04-07
IL290863A (en) 2022-04-01
KR20220051246A (ko) 2022-04-26
CA3149401A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
Heier et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies
Escobar-Barranco et al. Dexamethasone implants in patients with naive or refractory diffuse diabetic macular edema
Rayess et al. Baseline choroidal thickness as a predictor for response to anti–vascular endothelial growth factor therapy in diabetic macular edema
Yoshida et al. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema
Dastjerdi et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study
Rehak et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study)
Bahrami et al. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
Berger et al. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME
Hayashi et al. Changes in diabetic macular oedema after phacoemulsification surgery
Chen et al. Levels of angiogenesis‐related vascular endothelial growth factor family in neovascular glaucoma eyes
Ozturk et al. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema
BR112022003811A2 (pt) Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução
Zhang et al. The relationship between anti-vascular endothelial growth factor and fibrosis in proliferative retinopathy: clinical and laboratory evidence
Wakabayashi et al. Aqueous concentrations of vascular endothelial growth factor in eyes with high myopia with and without choroidal neovascularization
Menke et al. Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab
Ozturk et al. Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema
Wen et al. Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion
Ferrone et al. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration
Takahashi et al. Effects of posterior vitreous detachment on aqueous humour levels of VEGF and inflammatory cytokines
Udaondo et al. Challenges in diabetic macular edema management: an expert consensus report
Zhao et al. Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab
Lipp et al. Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis
Yodoi et al. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization
Yamaike et al. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
Houben et al. Efficacy of multiple dexamethasone intravitreal implants for refractory retinal vein occlusion-related macular edema and effect of prior vitrectomy